Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18 569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001)

International Journal of Antimicrobial Agents

Volumn 22, Issue 6, 2003, Pages 551-556

  Jones, Ronald N ^a,b   Sader, Helio S ^a,c   Beach, Mondell L ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antimicrobial resistance; Gram negative bacilli; Non fermentative; Sentry

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; DRUG SCREENING; FERMENTATION; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 0345549448     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00245-0     Document Type: Article

References (23)

1. Bergogne-Berezin E., Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:1996;148-165.
2. Denton M., Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev. 11:1998;57-80.
3. Quinn J.P. Clinical problems posed by multiresistant nonfermenting Gram-negative pathogens. Clin. Infect. Dis. 27:(Suppl 1):1998;117-124.
4. Zinner S.H. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria. Clin. Infect. Dis. 29:1999;490-494.
5. Gales A.C., Jones R.N., Turnidge J., Rennie R., Ramphal R. Characterisation of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32:(Suppl 2):2001;146-155.
6. Hanberger H., Diekema D., Fluit A., et al. Surveillance of antibiotic resistance in European ICUs. J. Hosp. Infect. 48:2001;161-176.
7. Jones R.N., Kirby J.T., Beach M.L., Biedenbach D.J., Pfaller M.A. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis. 43:2002;239-243.
8. National Nosocomial Infections Surveillance (NNIS) system report: data summary from October 1986-April 1998, issued June 1998. Am J Infect Control 1998; 26:522-33.
9. Gales A.C., Jones R.N., Forward K.R., Linares J., Sader H.S., Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis. 32:(Suppl 2):2001;S104-S113.
10. McDonald L.C., Banerjee S.N., Jarvis W.R. Seasonal variation of Acinetobacter infections: 1987-1996. Nosocomial Infections Surveillance System. Clin. Infect. Dis. 29:1999;1133-1137.
11. Mathevon T., Souweine B., Traoré O., Aublet B., Caillaud D. ICU-acquired nosocomial infection: impact of delay of adequate antibiotic treatment. Scand. J. Infect. Dis. 34:2002;831-835.
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 6th ed. Approved document M7-A6. Wayne, PA: NCCLS, 2003.
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 13th Informational Supplement M100-S13. Wayne, PA: NCCLS, 2003.
14. Bouza E., Munoz P. Monotherapy versus combination therapy for bacterial infections. Med. Clin. North Am. 84:2000;1357-1389.
15. Harris A.D., Smith D., Johnson J.A., Bradham D.D., Roghmann M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalised patients. Clin. Infect. Dis. 34:2002;340-345.
16. Carmeli Y., Troillet M., Eliopoulos G.M., Samore M.H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1999;1379-1382.
17. Newhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units. J. Am. Med. Assoc. 289:2003;885-889.
18. Cisneros J.M., Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin. Microbiol. Infect. 8:2002;687-693.
19. Gales A.C., Reis A.O., Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39:2001;183-190.
20. Levin A.S., Barone A.A., Penco J., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28:1999;1008-1011.
21. Levin A.S., Levy C.E., Manrique A.E., Medeiros E.A., Costa S.F. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int. J. Antimicrob. Agents. 21:2003;58-62.
22. Rahal J.J., Urban C., Segal-Maurer S. Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin. Infect. Dis. 34:2002;499-503.
23. Wood G.C., Hanes S.D., Croce M.A., Fabian T.C., Boucher B.A. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin. Infect. Dis. 34:2002;1425-1430.